• Evaxion discussed its Q2 2026 business update and financial results on Aug. 20, led by CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, CFO Thomas Schmidt.
• Management set an October ESMO presentation for three-year Phase 2 EVX-01 melanoma data, including standalone vaccine and anti-PD-1 combination outcomes.
• Earlier EVX-01 readouts cited 75% overall response rate, 25% complete responses, 92% still in response; 86% vaccine targets triggered tumor-specific responses.
• Introduced preclinical EVX-05 glioblastoma off-the-shelf vaccine with Duke; target discovery completed, 16 ERV fragments selected from about 1.5 million.
• Cash was USD 14 million at quarter-end; net loss USD 3.7 million; runway reiterated into H2 2027, supported by an ATM facility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.